Research programme: cancer gene therapy - Transave
Alternative Names: SLIT™ TR03; TR 03Latest Information Update: 04 Nov 2017
At a glance
- Originator Transave
- Class Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA
- 11 Sep 2005 This programme is still in active development - (BIO-2005)
- 18 Aug 2004 Preclinical trials in Non-small cell lung cancer in USA (unspecified route)